10-K: Aligos 2025 10-K: Pipeline Progress Amidst Going Concern

Aligos Therapeutics reports continued pipeline advancement in HBV, MASH, and coronavirus programs, alongside significant net losses and substantial doubt about its ability to continue as a going concern.

Summary

• Aligos Therapeutics is a clinical-stage biotechnology company focused on liver diseases and viral infections, including chronic HBV, MASH, obesity, and coronavirus infections.
• The company reported a net loss of $24.2 million for the year ended December 31, 2025, a significant improvement from the $131.2 million net loss in 2024.
• Cash, cash equivalents, and short-term investments totaled $77.8 million as of December 31, 2025, up from $56.9 million in 2024, primarily due to recent capital raises.
• Pevifoscorvir sodium, a Capsid Assembly Modulator (CAM-E) for chronic HBV, completed a 96-week Phase 1 study showing robust HBV DNA and antigen reductions, and is now in a Phase 2 B-SUPREME study.
• ALG055009, a THR-beta agonist for MASH and obesity, met its primary endpoint in a Phase 2a study with statistically significant reductions in liver fat (up to 46.2% placebo-adjusted median relative reduction at Week 12).
• Preclinical data for ALG055009 suggest synergistic weight loss when combined with incretin receptor agonists in diet-induced obese mice, with up to 40% body weight loss in combination with tirzepatide.
• ALG097558, a ritonavir-free pan-coronavirus protease inhibitor, completed a Phase 1 study showing it is at least 3-fold more potent than nirmatrelvir in cell-based assays and is now in a Phase 2 clinical study for COVID-19.
• The company's recurring losses from operations and negative cash flows raise substantial doubt about its ability to continue as a going concern beyond the third quarter of 2026.
• Aligos completed private placements in October 2023 and February 2025, generating gross proceeds of $92.1 million and $105.0 million, respectively.
• Research and development expenses decreased slightly to $69.5 million in 2025 from $70.3 million in 2024, partly due to increased government funding for the coronavirus program.
• General and administrative expenses decreased to $20.7 million in 2025 from $22.8 million in 2024, mainly due to reduced legal and IP spending.
• The company has federal net operating loss carryforwards of $92.5 million and state NOL carryforwards of $105.7 million as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative outlook. While pipeline assets show promising clinical and preclinical data, the persistent significant net losses and the explicit 'going concern' warning overshadow the scientific progress, indicating substantial financial instability and high investment risk.

Positives

• Pevifoscorvir sodium (HBV CAM-E) demonstrated profound and durable HBV DNA reductions, with 100% of HBeAg+ subjects achieving HBV DNA <LLOQ at Week 96 in Phase 1 monotherapy, and concurrent multi-log reductions in HBV antigens, suggesting potential cccDNA inhibition.
• ALG055009 (MASH/Obesity THR-beta agonist) met its primary endpoint in a Phase 2a study, showing statistically significant reductions in liver fat (up to 46.2% placebo-adjusted median relative reduction) and a favorable tolerability profile.
• Preclinical data for ALG055009 showed synergistic fat mass loss and enhanced body weight loss (up to 40%) when combined with incretin receptor agonists in obese mice.
• ALG097558 (pan-coronavirus PI) demonstrated at least 3-fold greater potency than nirmatrelvir in cell-based assays and an acceptable PK profile in Phase 1, suggesting it can be dosed twice daily without ritonavir co-dosing.
• The coronavirus program (ALG097558) received approximately $15.3 million in federal funding from NIH/NIAID for preclinical and clinical studies.
• The company successfully raised $105.0 million in gross proceeds from a private placement in February 2025, strengthening its capital position in the short term.
• Net loss significantly decreased to $24.2 million in 2025 from $131.2 million in 2024, largely due to a positive change in the fair value of 2023 Common Warrants.

Negatives

• The company has incurred significant recurring losses from operations and negative cash flows since inception, with an accumulated deficit of $642.2 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond the third quarter of 2026, requiring additional funding or significant curtailment of operations.
• Previous drug candidates, ALG-010133 (HBV STOPS) and ALG-020572 (HBV ASO), were discontinued in 2022 due to insufficient antiviral activity and unanticipated serious adverse events (ALT flares), respectively.
• Further clinical evaluation of ALG-125755 (HBV siRNA) is not prioritized with current funding and requires additional external funding.
• The company has never generated revenue from product sales and does not anticipate doing so for several years, if ever.
• The report of the independent registered public accounting firm for 2025 includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.

Risks

• The company is a clinical-stage biotechnology company with a limited operating history and no products approved for commercial sale, making future viability difficult to assess.
• Substantial additional financing will be required to achieve goals, and failure to obtain this capital could force delays, reductions, or termination of product development or commercialization efforts.
• Drug candidates may cause undesirable side effects or have other properties that could delay or halt clinical development, prevent marketing approval, or limit commercial potential.
• Dependence on collaborations with third parties for development exposes the company to risks if collaborations are unsuccessful or partners do not commit sufficient resources.
• Developing drug candidates in combination with other therapies exposes the company to additional risks, including issues with the co-administered therapies.
• Significant competition from multinational pharmaceutical companies and established biotechnology companies with greater resources could negatively impact commercial opportunities.
• Inability to obtain, maintain, protect, and enforce sufficient patent and other intellectual property protection could allow competitors to develop similar products.
• Third parties may initiate legal proceedings alleging infringement of intellectual property rights, leading to uncertain outcomes and potential negative impacts.
• Failure to comply with obligations in licensing agreements (e.g., with Emory University and KU Leuven) could lead to termination of licenses and loss of intellectual property rights.
• High dependence on key personnel, and inability to attract, motivate, and retain highly qualified personnel, could hinder business strategy implementation.
• The regulatory approval processes are lengthy, expensive, complex, and inherently unpredictable, with no guarantee of approval for any drug candidate.
• Interim, topline, and preliminary data from clinical trials may differ materially from final data, impacting future results and regulatory decisions.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Changes in drug candidate manufacturing or formulation may result in additional costs or delays.
• Even if marketing approval is received, products may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Adverse events in therapeutic areas of focus could damage public perception of drug candidates and negatively affect the business.
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expense and penalties for non-compliance.
• Inability to obtain approval outside the United States would limit market opportunities.
• Risks associated with international trade policies (e.g., tariffs, U.S. BIOSECURE Act) or international operations could harm the business.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, shutdowns) could hinder timely review and approval of products.
• Market opportunities for drug candidates may be smaller than estimated, or approval may be based on a narrower patient population definition.
• Inability to identify or discover other drug candidates, or failure to capitalize on programs with greater commercial opportunity, could harm the business.
• Failure to obtain fast track, breakthrough therapy, or priority review designations, or accelerated approval, may delay development and review.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization of approved products.
• Current and future healthcare reform legislation (e.g., IRA, OBBBA) may increase the difficulty and cost of commercialization and affect prices.
• Failure to comply with data privacy and protection laws (e.g., GDPR, CCPA, DSP) could lead to investigations, penalties, and adverse publicity.
• Information technology system failures or security breaches could disrupt operations and expose the company to legal, financial, and reputational harm.
• Reliance on third parties for manufacturing nonclinical and clinical drug supplies increases the risk of insufficient quantities or unacceptable costs.
• Relationships with customers and third-party payors may be subject to anti-kickback, fraud and abuse, false claims, and transparency laws.
• Changes in patent law could diminish the value of patents, impairing the ability to protect drug candidates.
• Intellectual property litigation could be expensive, time-consuming, and unsuccessful, and issued patents could be found invalid or unenforceable.
• Inability to protect the confidentiality of trade secrets would harm the business and competitive position.
• Inadequate protection of trademarks and trade names could hinder name recognition and adversely affect the business.
• Fluctuations in tax obligations and effective tax rate could materially and adversely affect results of operations.
• Future sales of common stock may cause dilution to stockholders and decline in stock price.

Future Outlook

The company expects research and development expenses to increase in future periods as it advances clinical trials for pevifoscorvir sodium and other drug candidates. Existing cash, cash equivalents, and short-term investments are projected to fund operations into the third quarter of 2026. Topline data for the Phase 2 B-SUPREME study are expected in 2027, with interim analyses planned for the first and second halves of 2026. The company is evaluating options, including potential out-licensing, to fund continued development of ALG055009 and seeking additional external funding for ALG097558.

Management Comments

• The Aligos team has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases, resulting in three potential best-in-class drug candidates.
• Pevifoscorvir sodium has the potential to replace standard of care NAs and become the backbone of next-generation treatments for chronic HBV infection.
• ALG055009 has the potential to become a best-in-class THR-beta agonist and could play an integral role in future combination regimens for MASH and obesity.
• ALG097558 is believed to be dosed twice daily without the requirement for ritonavir co-dosing based on Phase 1 clinical studies conducted to date.
• The company's strategy is to develop pharmacologically optimized drug candidates designed to achieve improved treatment outcomes in liver and viral diseases.
• Management believes that the benefits of increased protection of the company's potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure the company outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.

Industry Context

StockSavvy.ai notes that Aligos Therapeutics operates in highly competitive and rapidly evolving biotechnology sectors, specifically targeting chronic HBV, MASH, obesity, and coronavirus infections. The company's strategy of developing 'best-in-class' candidates in these areas positions it against established pharmaceutical giants and numerous smaller biotechs. The MASH and obesity markets are seeing increased activity with recent FDA approvals (Madrigal's resmetirom and Novo Nordisk's semaglutide), indicating both market validation and intense competition. Similarly, the chronic HBV and coronavirus fields are crowded with various mechanisms of action under development, highlighting the need for highly differentiated and efficacious therapies to gain market share. The reliance on external funding and collaborations is a common industry practice for clinical-stage companies, but also introduces execution risks.

Comparison to Industry Standards

• Pevifoscorvir sodium's Phase 1 data suggest potential superiority to current standard of care nucleos(t)ide analogs (NAs) like tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) in achieving HBV DNA levels <LLOQ after 48 weeks, subject to confirmation in further studies.
• ALG055009 demonstrated approximately 50-fold higher potency and 2-fold greater selectivity for the THR-beta receptor compared to resmetirom (Madrigal Pharmaceuticals, Inc.), an FDA-approved THR-beta agonist for MASH, in side-by-side cell-based experiments.
• ALG097558 showed at least 3-fold greater potency in cell-based assays against SARS-CoV-2 variants (including Omicron) compared to nirmatrelvir (Pfizer's Paxlovid), an approved CoV PI, and appears to not require ritonavir boosting, differentiating it from Paxlovid.

Corporate Governance

Legal Proceedings

• Not currently involved in any legal proceedings that are, individually or in the aggregate, material to the business, results of operations, or financial condition.

Related Party Transactions

• Baker Brothers Life Sciences, L.P. (Lead Investor) participated in the February 2025 PIPE offering and received director nomination rights as part of a letter agreement.
• Certain holders of 5% or more of capital stock acquired pre-funded and common warrants in the October 2023 and February 2025 private placements.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from future capital raises, continued stock price volatility due to financial uncertainty and clinical trial outcomes, and limited ability to influence corporate matters due to concentrated ownership and anti-takeover provisions.
• **Employees:** Dependence on key personnel is high, and the going concern warning could impact morale and retention. Stock-based compensation is a significant part of their remuneration.
• **Customers/Patients:** Potential for novel therapies in chronic HBV, MASH, obesity, and coronavirus infections, but also risks of clinical trial failures or discontinuation of drug candidates.
• **Creditors/Investors:** High risk due to recurring losses, negative cash flows, and the 'going concern' qualification, making future financing potentially more difficult or costly.
• **Partners (Emory, KU Leuven, Amoytop):** Continued collaboration and milestone payments are contingent on the company's financial health and successful program advancement.

Next Steps

• Continue the Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic HBV infection, with first interim analysis expected in H1 2026 and second in H2 2026, and topline data expected in 2027.
• Evaluate a variety of options, including potential out-licensing, to fund continued development of ALG055009 for MASH and obesity.
• Seek additional external funding (e.g., from governmental agencies) and/or collaborations (e.g., platform trials) to support future studies for ALG097558 for COVID-19 and future coronavirus pandemics.
• Advance ALG-170675 (HBV ASO) into IND-enabling studies, with current development costs in China funded by partner Amoytop.
• Continue ongoing work aimed at selecting a clinical development candidate for hepatitis delta virus (HDV) coinfection using a proprietary ASO approach.
• Identify access to future capital to fund continued operations beyond the third quarter of 2026.

Key Dates

Recommendation

Despite promising early-stage clinical data for its pipeline candidates, the company's explicit 'substantial doubt about its ability to continue as a going concern' beyond Q3 2026, coupled with a history of significant recurring losses and the discontinuation of previous drug candidates due to efficacy/safety issues, presents an extremely high level of financial risk. While recent capital raises provide temporary relief, the fundamental business model of a clinical-stage biotech with no product revenue and a short cash runway indicates severe financial distress. The stock is highly speculative, and the risk of further dilution or operational curtailment is significant, making it an unfavorable investment for seasoned investors or institutions.

Keywords

Biotechnology, HBV, Hepatitis B, MASH, NASH, Obesity, Coronavirus, COVID-19, Drug Development, Clinical Trials, SEC Filing, 10-K, Financials, Capital Raise, Going Concern, Pevifoscorvir sodium, ALG055009, ALG097558, Capsid Assembly Modulator, THR-beta agonist, Protease Inhibitor, Pharmaceuticals, Intellectual Property